These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28794806)

  • 21. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
    Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
    PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
    Custodio A; Feliu J
    Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.
    Motta R; Cabezas-Camarero S; Torres-Mattos C; Riquelme A; Calle A; Montenegro P; Sotelo MJ
    J Clin Transl Res; 2021 Dec; 7(6):771-785. PubMed ID: 34988329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Primary Tumor Location on Second- or Later-Line Treatment With Anti-Epidermal Growth Factor Receptor Antibodies in Patients With Metastatic Colorectal Cancer: A Retrospective Multi-Center Study.
    Archwamety A; Teeyapun N; Siripoon T; Poungvarin N; Tanasanvimon S; Sirachainan E; Akewanlop C; Korphaisarn K
    Front Oncol; 2022; 12():813009. PubMed ID: 35242708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers.
    Salem ME; Weinberg BA; Xiu J; El-Deiry WS; Hwang JJ; Gatalica Z; Philip PA; Shields AF; Lenz HJ; Marshall JL
    Oncotarget; 2017 Oct; 8(49):86356-86368. PubMed ID: 29156800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
    Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
    Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted Therapy in Metastatic Colorectal Cancer: Current Standards and Novel Agents in Review.
    DeStefanis RA; Kratz JD; Emmerich PB; Deming DA
    Curr Colorectal Cancer Rep; 2019 Apr; 15(2):61-69. PubMed ID: 31130830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular Profiling in Metastatic Colorectal Cancer.
    Armstrong SA; Malley R; Weinberg BA
    Oncology (Williston Park); 2020 Sep; 34(9):352-355. PubMed ID: 32965665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M
    Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
    Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
    BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician.
    Afrăsânie VA; Marinca MV; Alexa-Stratulat T; Gafton B; Păduraru M; Adavidoaiei AM; Miron L; Rusu C
    Radiol Oncol; 2019 Sep; 53(3):265-274. PubMed ID: 31553708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Tumor Sidedness, RAS and BRAF Mutations and MSI Status as Prognostic Factors in Patients with Colorectal Liver Metastases Treated with Surgery and Thermal Ablation: Results from the Amsterdam Colorectal Liver Met Registry (AmCORE).
    Dijkstra M; Nieuwenhuizen S; Puijk RS; Timmer FEF; Geboers B; Schouten EAC; Opperman J; Scheffer HJ; de Vries JJJ; Versteeg KS; Lissenberg-Witte BI; van den Tol MP; Meijerink MR
    Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.
    Biller LH; Schrag D
    JAMA; 2021 Feb; 325(7):669-685. PubMed ID: 33591350
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
    Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.
    Mauri D; Kamposioras K; Matthaios D; Tolia M; Nixon I; Dambrosio M; Zarkavelis G; Papadimitriou K; Petricevic B; Kountourakis P; Kopecky J; Grašič Kuhar C; Popovic L; Chilingirova NP; De Mello RA; Dedić Plavetić N; Katsanos K; Mostert B; Alongi F; de Bari B; Corradini S; Kampletsas E; Gazouli I; Gkoura S; Amylidi AL; Valachis A
    Oncol Res Treat; 2022; 45(4):216-221. PubMed ID: 34999585
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Radanova M; Mihaylova G; Stoyanov GS; Draganova V; Zlatarov A; Kolev N; Dimitrova E; Conev N; Ivanova D
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628934
    [No Abstract]   [Full Text] [Related]  

  • 38. Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer.
    Wang C; Sandhu J; Fakih M
    Oncologist; 2022 Mar; 27(2):104-109. PubMed ID: 35641204
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches.
    Li F; Lin Y; Li R; Shen X; Xiang M; Xiong G; Zhang K; Xia T; Guo J; Miao Z; Liao Y; Zhang X; Xie L
    Front Pharmacol; 2023; 14():1165666. PubMed ID: 37927605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment sequencing in metastatic colorectal cancer.
    Modest DP; Pant S; Sartore-Bianchi A
    Eur J Cancer; 2019 Mar; 109():70-83. PubMed ID: 30690295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.